Stock Events

Stock Events

Acadia Pharmaceuticals 

€18.98
123
-€0.14-0.75% Monday 06:03

Statistics

Day High
18.98
Day Low
18.98
52W High
23.57
52W Low
12.59
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q4 2025
Next
0.04
0.48
0.92
1.35
Expected EPS
0.04310216873
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DR6.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, develops drugs that directly compete in the neurological and psychiatric drug markets.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly and Company offers a range of products that target the central nervous system, making it a direct competitor in the psychiatric and neurological drug markets.
Novartis
NVS
Mkt Cap279.67B
Novartis AG has a strong portfolio in neuroscience, competing in the development and marketing of drugs for psychiatric and neurological disorders.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a diversified portfolio that includes treatments for neurological conditions, directly competing with Acadia's offerings.
Biogen
BIIB
Mkt Cap27.62B
Biogen Inc. focuses on neurology, developing treatments for diseases like multiple sclerosis and Alzheimer's, areas that overlap with Acadia's focus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical Industries Limited has a broad portfolio that includes CNS (central nervous system) drugs, making it a competitor in the neurological and psychiatric medication market.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie Inc. has a growing interest in neuroscience, including R&D in Parkinson's and Alzheimer's, which competes with Acadia's focus areas.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is involved in the development of drugs that target neurological disorders, positioning it as a competitor in the same therapeutic area as Acadia.
Alkermes
ALKS
Mkt Cap5.69B
Alkermes plc has a focus on central nervous system (CNS) disorders, including schizophrenia and depression, directly competing with some of Acadia's key products.

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Show more...
CEO
Mr. Stephen R. Davis J.D.
Employees
510
Country
United States
ISIN
US0042251084

Listings

LSE
GB
0A4W.LSE
MU
DE
DR6.MU
XNAS
US
ACAD
STU
DE
DR6.STU

0 Comments

Share your thoughts

FAQ

What is Acadia Pharmaceuticals stock price today?▼
The current price of DR6.MU is €18.98 EUR — it has decreased by -0.75% in the past 24 hours. Watch Acadia Pharmaceuticals stock price performance more closely on the chart.
What is Acadia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Acadia Pharmaceuticals stocks are traded under the ticker DR6.MU.
How many employees does Acadia Pharmaceuticals have?▼
As of May 06, 2026, the company has 510 employees.
In which sector is Acadia Pharmaceuticals located?▼
Acadia Pharmaceuticals operates in the Other sector.
When did Acadia Pharmaceuticals complete a stock split?▼
Acadia Pharmaceuticals has not had any recent stock splits.
Where is Acadia Pharmaceuticals headquartered?▼
Acadia Pharmaceuticals is headquartered in San Diego, United States.